Preclinical Efficacy of IMM-BCP-01, a Highly Active Patient-Derived Anti-SARS-CoV-2 Antibody Cocktail
P. A. Nikitin, J. M. DiMuzio, J. P. Dowling, N. B. Patel, J. L. Bingaman-Steele, C. Nicolescu, B. C. Heimbach, N. Henriquez, E. L. Sikorsky, A. Polley, R. J. Howanski, M. Nath, H. Shukla, S. M. Scheaffer, J. P. Finn, , M. K. Robinson
The paper identifies and characterizes an antibody cocktail, IMM-BCP-01, that neutralizes SARS-CoV-2 variants in vitro and inhibits infection in vivo through Spike Trimer dissociation and effector responses.
bioRxiv · Oct 18, 2021 · PreprintImmunology